Search Results - "Zwarthoff, Ellen C."

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment? by van Rhijn, Bas W.G., Mertens, Laura S., Mayr, Roman, Bostrom, Peter J., Real, Francisco X., Zwarthoff, Ellen C., Boormans, Joost L., Abas, Cheno, van Leenders, Geert J.L.H., Götz, Stefanie, Hippe, Katrin, Bertz, Simone, Neuzillet, Yann, Sanders, Joyce, Broeks, Annegien, van der Heijden, Michiel S., Jewett, Michael A.S., Marquez, Mirari, Stoehr, Robert, Zlotta, Alexandre R., Eckstein, Markus, Soorojebally, Yanish, Roshani, Hossain, Burger, Maximilian, Otto, Wolfgang, Radvanyi, François, Sirab, Nanor, Pouessel, Damien, Wullich, Bernd, van der Kwast, Theo H., Malats, Núria, Hartmann, Arndt, Allory, Yves, Zuiverloon, Tahlita C.M.

“…Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer (BC). FGFR3 mutations are common in noninvasive BC and associated with…”
Get full text

Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer by Seiler, Roland, Gibb, Ewan A, Wang, Natalie Q, Oo, Htoo Zarni, Lam, Hung-Ming, van Kessel, Kim E, Voskuilen, Charlotte S, Winters, Brian, Erho, Nicholas, Takhar, Mandeep M, Douglas, James, Vakar-Lopez, Funda, Crabb, Simon J, van Rhijn, Bas W G, Fransen van de Putte, Elisabeth E, Zwarthoff, Ellen C, Thalmann, George N, Davicioni, Elai, Boormans, Joost L, Dall'Era, Marc, van der Heijden, Michiel S, Wright, Jonathan L, Black, Peter C

“…After cisplatin-based neoadjuvant chemotherapy (NAC), 60% of patients with muscle-invasive bladder cancer (MIBC) still have residual invasive disease at…”
Get full text

Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study by Frantzi, Maria, van Kessel, Kim E, Zwarthoff, Ellen C, Marquez, Mirari, Rava, Marta, Malats, Núria, Merseburger, Axel S, Katafigiotis, Ioannis, Stravodimos, Konstantinos, Mullen, William, Zoidakis, Jerome, Makridakis, Manousos, Pejchinovski, Martin, Critselis, Elena, Lichtinghagen, Ralph, Brand, Korbinian, Dakna, Mohammed, Roubelakis, Maria G, Theodorescu, Dan, Vlahou, Antonia, Mischak, Harald, Anagnou, Nicholas P

“…Urothelial bladder cancer presents high recurrence rates, mandating continuous monitoring via invasive cystoscopy. The development of noninvasive tests for…”
Get full text

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy by Kompier, Lucie C, Lurkin, Irene, van der Aa, Madelon N M, van Rhijn, Bas W G, van der Kwast, Theo H, Zwarthoff, Ellen C

“…Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their disease and current chemotherapy treatment only marginally increases…”
Get full text

Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up by Critelli, Rossana, Fasanelli, Francesca, Oderda, Marco, Polidoro, Silvia, Assumma, Manuela Bianca, Viberti, Clara, Preto, Mirko, Gontero, Paolo, Cucchiarale, Giuseppina, Lurkin, Irene, Zwarthoff, Ellen C, Vineis, Paolo, Sacerdote, Carlotta, Matullo, Giuseppe, Naccarati, Alessio

“…Most bladder cancer (BC) patients need life-long, invasive and expensive monitoring and treatment, making it a serious burden on the health system. Thus, there…”
Get full text

The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder by Doeveren, Thomas, Nakauma‐Gonzalez, Jose A., Mason, Andrew S., Leenders, Geert J. L. H., Zuiverloon, Tahlita C. M., Zwarthoff, Ellen C., Meijssen, Isabelle C., Made, Angelique C., Heijden, Antoine G., Hendricksen, Kees, Rhijn, Bas W. G., Voskuilen, Charlotte S., Riet, Job, Dinjens, Winand N. M., Dubbink, Hendrikus J., Werken, Harmen J. G., Boormans, Joost L.

“…The risk of developing urothelial carcinoma of the bladder (UCB) in patients treated by radical nephroureterectomy (RNU) for an upper urinary tract urothelial…”
Get full text

Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX2, TBX3, GATA2, and ZIC4 as pTa-Specific Prognostic Markers by Kandimalla, Raju, van Tilborg, Angela A.G, Kompier, Lucie C, Stumpel, Dominique J.P.M, Stam, Ronald W, Bangma, Chris H, Zwarthoff, Ellen C

“…Abstract Background DNA methylation markers could serve as useful biomarkers, both as markers for progression and for urine-based diagnostic assays. Objective…”
Get full text

Molecular Grade ( FGFR3 /MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer by van Rhijn, Bas W.G, Zuiverloon, Tahlita C.M, Vis, André N, Radvanyi, François, van Leenders, Geert J.L.H, Ooms, Bert C.M, Kirkels, Wim J, Lockwood, Gina A, Boevé, Egbert R, Jöbsis, Adriaan C, Zwarthoff, Ellen C, van der Kwast, Theo H

“…Abstract Background The European Organization for Research and Treatment of Cancer (EORTC) risk scores are not validated in an independent patient population…”
Get full text

The use of molecular analyses in voided urine for the assessment of patients with hematuria by Beukers, Willemien, Kandimalla, Raju, van Houwelingen, Diandra, Kovacic, Hrvoje, Chin, Jie-Fen D, Lingsma, Hester F, Dyrskjot, Lars, Zwarthoff, Ellen C

“…Patients presenting with painless hematuria form a large part of the urological patient population. In many cases, especially in younger patients, the cause of…”
Get full text

Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes by Lurkin, Irene, Stoehr, Robert, Hurst, Carolyn D, van Tilborg, Angela A G, Knowles, Margaret A, Hartmann, Arndt, Zwarthoff, Ellen C

“…Recently a number of randomized trials have shown that patients with advanced colorectal cancer do not benefit from therapies targeting the epidermal growth…”
Get full text

Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications by van Rhijn, Bas W G, Musquera, Mireia, Liu, Liyang, Vis, André N, Zuiverloon, Tahlita C M, van Leenders, Geert J L H, Kirkels, Wim J, Zwarthoff, Ellen C, Boevé, Egbert R, Jöbsis, Adriaan C, Bapat, Bharati, Jewett, Michael A S, Zlotta, Alexandre R, van der Kwast, Theo H

“…Currently, the use of two classification systems for bladder cancer grade is advocated in clinical guidelines because the WHO2004 classification has not been…”
Get full text

Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial by van der Aa, Madelon N M, Steyerberg, Ewout W, Bangma, Chris, van Rhijn, Bas W G, Zwarthoff, Ellen C, van der Kwast, Theo H

“…We evaluated the influence of knowledge of urine test outcome on the accuracy of cystoscopy (diagnostic review bias) during surveillance in patients with low…”
Get more information

Prediction of Progression of Non–Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study by Burger, Maximilian, van der Aa, Madelon N.M, van Oers, Johanna M.M, Brinkmann, Anke, van der Kwast, Theodorus H, Steyerberg, Ewout C, Stoehr, Robert, Kirkels, Wim J, Denzinger, Stefan, Wild, Peter J, Wieland, Wolf F, Hofstaedter, Ferdinand, Hartmann, Arndt, Zwarthoff, Ellen C

“…Abstract Objectives The clinical management of non–muscle-invasive urothelial cell carcinoma of the bladder (UCC) is challenging, as it has a marked tendency…”
Get full text

The Mn1 transcription factor acts upstream of Tbx22 and preferentially regulates posterior palate growth in mice by Liu, Wenjin, Lan, Yu, Pauws, Erwin, Meester-Smoor, Magda A, Stanier, Philip, Zwarthoff, Ellen C, Jiang, Rulang

“…The mammalian secondary palate exhibits morphological, pathological and molecular heterogeneity along the anteroposterior axis. Although the cell proliferation…”
Get full text

TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors by Dubbink, Hendrikus J., Bakels, Hannah, Post, Edward, Zwarthoff, Ellen C., Verdijk, Robert M.

“…Hot spot mutations in the promoter region of telomerase reverse transcriptase ( TERT promoter mutations) occur frequently in tumors of neuroectodermal origin…”
Get full text

A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy by de Jong, Florus C., Iflé, Iris G., van der Made, Angelique C., Kooper, Denise, de Jong, Joep J., Franckena, Martine, Zuiverloon, Tahlita C.M., van Criekinge, Wim, Incrocci, Luca, Zwarthoff, Ellen C., Boormans, Joost L.

“…We analyzed the diagnostic value of a molecular urine test to detect recurrent disease in bladder cancer patients treated by (chemo)radiation and showed that a…”
Get full text

Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia by Papathomas, Thomas G, Oudijk, Lindsey, Zwarthoff, Ellen C, Post, Edward, Duijkers, Floor A, van Noesel, Max M, Hofland, Leo J, Pollard, Patrick J, Maher, Eamonn R, Restuccia, David F, Feelders, Richard A, Franssen, Gaston J H, Timmers, Henri J, Sleijfer, Stefan, de Herder, Wouter W, de Krijger, Ronald R, Dinjens, Winand N M, Korpershoek, Esther

“…Hotspot mutations in the promoter of the telomerase reverse transcriptase (TERT) gene have been recently reported in human cancers and proposed as a novel…”
Get full text

A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene by Hurst, Carolyn D, Zuiverloon, Tahlita C M, Hafner, Christian, Zwarthoff, Ellen C, Knowles, Margaret A

“…Activating mutations in the PIK3CA gene have been identified in a variety of human malignancies and are commonly detected in hotspot codons located in the…”
Get full text

A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable by van Kessel, Kim E M, van de Werken, Harmen J G, Lurkin, Irene, Ziel-van der Made, Angelique C J, Zwarthoff, Ellen C, Boormans, Joost L

“…Neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) provides a small but significant survival benefit. Nevertheless, controversies on…”
Get full text

Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome by VAN RHIJN, Bas W. G, VIS, André N, VAN DER KWAST, Theo H, KIRKELS, Wim J, RADVANYI, Francois, OOMS, Engelbert C. M, CHOPIN, Dominique K, BOEVE, Egbert R, JÖBSIS, Adriaan C, ZWARTHOFF, Ellen C

“…Fibroblast growth factor receptor 3 (FGFR3) mutations were recently found at a high frequency in well-differentiated urothelial cell carcinoma (UCC). We…”
Get full text